论文部分内容阅读
目的:研究NK细胞活化性受体CD226(DNAM-1)的配体CD112(nectin-2)在结肠癌细胞系中的表达情况,检测结肠癌组织中CD112的表达,分析其与临床病例组织病理分级的关系。方法:流式细胞术(FCM)及Westernblot检测结肠癌细胞系(Colo205、SW116、SW480)上CD112的表达情况。以免疫组织化学法检测90例结肠癌组织和30例正常结肠组织对照中CD112的表达情况。结果:FCM检测CD112在Co-lo205、SW116和SW480结肠癌细胞系的阳性表达率分别为99.3%、47.1%和98.7%。CD112在结肠癌组织中其阳性表达率为42.35%,在正常结肠组织对照中阳性表达率为10%,两组之间的阳性表达率差异有统计学意义(P=0.001)。不同分化程度、不同Dukes分期结肠癌组织之间CD112的阳性表达率差异无统计学意义(P=0.997、P=0.777);CD112阳性表达强度与分化程度和Dukes分期之间无相关性(r=-0.006、r=-0.032)。结论:CD112在结肠癌组织中表达高于正常对照组织,有统计学意义。在结肠癌细胞系表达较高。可以试图通过基因转染上调结肠癌组织中CD112的表达强度,利用CD112与NK细胞活化性受体CD226结合,活化NK细胞并启动NK细胞对结肠癌的杀伤作用,为结肠癌临床免疫治疗提供思路和理论依据。
OBJECTIVE: To investigate the expression of CD112 (nectin-2), a ligand of the NK cell activating receptor CD226 (DNAM-1), in colon cancer cell lines, and to detect the expression of CD112 in colon cancer tissues, and to analyze its association with clinical case histopathology. Graded relationship. Methods: Flow cytometry (FCM) and Western blot were used to detect the expression of CD112 in colon cancer cell lines (Colo205, SW116, SW480). Immunohistochemistry was used to detect the expression of CD112 in 90 cases of colon cancer tissues and 30 cases of normal colon tissues. RESULTS: The positive expression rates of CD112 in Co-lo205, SW116 and SW480 colon cancer cell lines were 99.3%, 47.1% and 98.7%, respectively. The positive expression rate of CD112 in colon cancer tissues was 42.35%, and the positive expression rate of CD112 in normal colon tissues was 10%. There was a significant difference in the positive expression rate between the two groups (P=0.001). There was no significant difference in the positive expression rate of CD112 between different differentiation stages and different Dukes stage colon cancer tissues (P=0.997, P=0.777). There was no correlation between CD112 positive expression intensity and differentiation degree and Dukes stage (r= -0.006, r = -0.032). Conclusion: The expression of CD112 in colorectal cancer tissue is higher than that in normal control tissues. It has statistical significance. High expression in colon cancer cell lines. It is possible to attempt to up-regulate the expression of CD112 in colon cancer tissue through gene transfection, and use CD112 to bind to NK cell activating receptor CD226 to activate NK cells and initiate the killing effect of NK cells on colon cancer so as to provide ideas for clinical immunotherapy of colon cancer. And theoretical basis.